Last reviewed · How we verify
NCT05904444
The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies
NA trial testing microperimetric biofeedback training in Macular Degeneration in 29 participants. Completed in 30 April 2023.
30 April 2023
Quick facts
| Lead sponsor | Aier Eye Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 15 August 2018 |
| Primary completion | 30 April 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- microperimetric biofeedback training
Conditions studied
- Macular Degeneration — all drugs for Macular Degeneration →
- Low Vision — all drugs for Low Vision →
- Stargardt Disease — all drugs for Stargardt Disease →
Sponsor
Aier Eye Hospital, Guangzhou
Who can join
Adults 12 to 80, any sex, with Macular Degeneration or Low Vision. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients who develop macular diseases have several clinical complications,such as central vision loss, the central scotoma of the visual field, the decrease of reading speed and fixation stability. At present, there is still no satisfactory effect in the prevention and treatment of advanced macular disease. A new rehabitation strategy named microperimetric biofeedback training has been shown to be effective in improving patients' visual appearance, but there is no consensus regarding the optimal methodology and standard of practice. Therefore, we designed a prospective clinical study to verify the effectiveness of MBFT and to determine an optimal plan.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The effect of duration between sessions on microperimetric biofeedback training in patients with maculopathies.
Zhou J, Hou J, Li S, Zhang J. · · 2024 · cited 1× · PMID 38822030 · DOI 10.1038/s41598-024-63327-x
Verify or expand the search:
- PubMed search for NCT05904444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
- NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting
- NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy · recruiting
- NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05904444 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aier Eye Hospital, Guangzhou
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing